

Healthcare: Devices

EzeCheck: India’s First ICMR Validated Non-Invasive Hemoglobin Screening Device

APPLICATION

To tackle the prevalence of anemia, mass scale screening in across the age groups are very crucial. Specially on the adolescent, school going children along with the pregnant and lactating mother, time-based intervention is required. EzeCheck will be useful for deploying in Government programs/ schemes, Hospital and Clinics, Blood Banks, CSR, NGOs, Pharma and Insurance companies, for detecting anemia within less than a minute and without pricking a single drop of blood from the human body.

COMPANY NAME	TECHNOLOGY READINESS LEVEL (TRL)	INTELLECTUAL PROPERTY
EzeRx Health Tech Private Limited	TRL: 9 (System Proven and Ready for Full Commercial Deployment)	Non-Invasive Hemoglobin Screening Device App No: 202021015008 PCT- PCT/IN2021/050336
FOUNDER’S NAME		
Partha Pratim Das Mahapatra		Completed 34 international filings and Granted 2 international patents.

PROBLEM ADDRESSED

- Globally two billion, in India more than 50% women and child are anemic.
- 2 out of every 3 women in India are anemic.
- Due to unavailability of noninvasive screening device, adolescent and school going children are not screened as expected.

ABOUT THE TECHNOLOGY

EzeCheck employs absorbance spectroscopy, a sophisticated technique for signal analysis and processing. This, combined with advanced artificial intelligence algorithms, enables accurate evaluation of hemoglobin levels with unparalleled precision and efficiency.

CURRENT TRACTIONS

Funds Raised So Far: \$2.18 Million

Revenue Run Rate: \$0.85 Million in FY 22-23

Employment Generated: 27

MILESTONES BY EZECHECK

EzeCheck screened 23 lakh individuals, detecting anemia in 7.5+ lakh people across 17+ states, 386+ districts, and seven international markets. Our partnership with Sun Pharma, the fourth-largest global specialty generic pharmaceutical company and Indian Oil Corporation, has strengthened our position. We remain committed to serving the healthcare industry with Next-gen technology to save lives and create a social impact.

SOCIAL IMPACT BY EZECHECK

 **Money Saved**-\$1.35 M+

 **Time Saved** -1064+ Years

 **Blood Saved** - 6,075+ Gallon

 **Medical waste Saved** -15.2+ Tons

 **Carbon Credit**- 46+ Kilotons

PRODUCT IMAGE



UNIQUE SELLING PROPOSITION

1. **Non Invasive, Infection free and painless**
2. **Affordable and accessible**
3. **Portable and rechargeable battery operated**
4. **Easy to train for semi-skilled manpower**
5. **IoT enabled, easy to integrate any third party application for quick treatment plan**
6. **Sustainability and Environment friendly**

END USERS/CUSTOMERS

•**End Users:** People suffering from anemia, pregnant and lactating mother, adolescent and school children

•**Customers:** Government programs/ schemes, Hospital and Clinics, Blood Banks, CSR, NGOs, Pharma and Insurance companies